The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. Psychiatry Research, 284:112749, February, 2020.
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis [link]Paper  doi  abstract   bibtex   
The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. Across four studies (one uncontrolled; three randomized, placebo-controlled; N = 117), within-group pre-post and pre-follow-up effects on anxiety and depression were large (Hedges’ gs=1.16 to 1.47) and statistically significant. Across three placebo-controlled studies, pre-post placebo-controlled effects were also large (gs = 0.82 to 0.83) and statistically significant. No serious adverse events were reported. Limitations include the small number of studies and risk for bias within studies. Results tentatively support future research on psilocybin for the treatment of anxiety and depression.
@article{goldberg_experimental_2020,
	title = {The experimental effects of psilocybin on symptoms of anxiety and depression: {A} meta-analysis},
	volume = {284},
	issn = {01651781},
	shorttitle = {The experimental effects of psilocybin on symptoms of anxiety and depression},
	url = {https://linkinghub.elsevier.com/retrieve/pii/S016517811930811X},
	doi = {10.1016/j.psychres.2020.112749},
	abstract = {The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. Across four studies (one uncontrolled; three randomized, placebo-controlled; N = 117), within-group pre-post and pre-follow-up effects on anxiety and depression were large (Hedges’ gs=1.16 to 1.47) and statistically significant. Across three placebo-controlled studies, pre-post placebo-controlled effects were also large (gs = 0.82 to 0.83) and statistically significant. No serious adverse events were reported. Limitations include the small number of studies and risk for bias within studies. Results tentatively support future research on psilocybin for the treatment of anxiety and depression.},
	language = {en},
	urldate = {2022-05-27},
	journal = {Psychiatry Research},
	author = {Goldberg, Simon B. and Pace, Brian T. and Nicholas, Christopher R. and Raison, Charles L. and Hutson, Paul R.},
	month = feb,
	year = {2020},
	pages = {112749},
}

Downloads: 0